|
|
|
|
|
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
|
94-3166458
|
(State or other jurisdiction
|
|
(I.R.S. Employer
|
of incorporation or organization)
|
|
Identification No.)
|
Large accelerated filer
o
|
|
Accelerated filer
x
|
|
|
|
Non-accelerated filer
o
|
|
Smaller reporting company
o
|
(Do not check if a smaller reporting company)
|
|
|
|
|
|
|
|
|
|
Page
number
|
|
||
|
||
|
||
|
||
|
||
|
||
|
|
|
|
|
|
Item 1.
|
Financial Statements
|
|
June 30,
2012 |
|
December 31,
2011 |
||||
|
(unaudited)
|
|
(1)
|
||||
ASSETS
|
|
|
|
|
|
||
Current assets:
|
|
|
|
|
|
||
Cash and cash equivalents
|
$
|
54,071
|
|
|
$
|
191,762
|
|
Short-term investments
|
—
|
|
|
8,107
|
|
||
Accounts receivable, net of allowances of $337 and $443 at June 30, 2012 and December 31, 2011, respectively
|
46,390
|
|
|
38,661
|
|
||
Inventories
|
25,170
|
|
|
18,107
|
|
||
Prepaid expenses
|
11,609
|
|
|
10,495
|
|
||
Deferred tax assets
|
11,197
|
|
|
10,352
|
|
||
Other current assets
|
7,164
|
|
|
6,107
|
|
||
Total current assets
|
155,601
|
|
|
283,591
|
|
||
Property and equipment, net
|
28,965
|
|
|
17,306
|
|
||
Non-current net investment in sales-type leases
|
9,826
|
|
|
8,785
|
|
||
Goodwill
|
113,034
|
|
|
28,543
|
|
||
Other intangible assets
|
87,242
|
|
|
4,231
|
|
||
Non-current deferred tax assets
|
—
|
|
|
11,677
|
|
||
Other assets
|
9,959
|
|
|
9,716
|
|
||
Total assets
|
$
|
404,627
|
|
|
$
|
363,849
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
||
Current liabilities:
|
|
|
|
|
|
||
Accounts payable
|
$
|
15,687
|
|
|
$
|
11,000
|
|
Accrued compensation
|
13,323
|
|
|
7,328
|
|
||
Accrued liabilities
|
9,956
|
|
|
8,901
|
|
||
Deferred service revenue
|
19,791
|
|
|
19,191
|
|
||
Deferred gross profit
|
14,478
|
|
|
14,210
|
|
||
Total current liabilities
|
73,235
|
|
|
60,630
|
|
||
Non-current deferred service revenue
|
18,471
|
|
|
18,966
|
|
||
Non-current deferred tax liabilities
|
22,124
|
|
|
—
|
|
||
Other long-term liabilities
|
3,277
|
|
|
1,339
|
|
||
Total liabilities
|
117,107
|
|
|
80,935
|
|
||
Stockholders’ equity:
|
|
|
|
|
|
||
Total stockholders’ equity
|
287,520
|
|
|
282,914
|
|
||
Total liabilities and stockholders’ equity
|
$
|
404,627
|
|
|
$
|
363,849
|
|
|
|
|
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2012
|
|
2011
|
|
2012
|
|
2011
|
||||||||
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Product revenues
|
$
|
59,269
|
|
|
$
|
46,218
|
|
|
$
|
107,793
|
|
|
$
|
88,793
|
|
Services and other revenues
|
16,115
|
|
|
14,787
|
|
|
31,734
|
|
|
29,372
|
|
||||
Total revenues
|
75,384
|
|
|
61,005
|
|
|
139,527
|
|
|
118,165
|
|
||||
Cost of revenues:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of product revenues
|
28,600
|
|
|
19,730
|
|
|
48,896
|
|
|
37,566
|
|
||||
Cost of services and other revenues
|
7,408
|
|
|
7,468
|
|
|
15,506
|
|
|
15,142
|
|
||||
Total cost of revenues
|
36,008
|
|
|
27,198
|
|
|
64,402
|
|
|
52,708
|
|
||||
Gross profit
|
39,376
|
|
|
33,807
|
|
|
75,125
|
|
|
65,457
|
|
||||
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development
|
5,499
|
|
|
5,280
|
|
|
11,993
|
|
|
10,120
|
|
||||
Selling, general and administrative
|
31,446
|
|
|
24,297
|
|
|
57,066
|
|
|
50,078
|
|
||||
Total operating expenses
|
36,945
|
|
|
29,577
|
|
|
69,059
|
|
|
60,198
|
|
||||
Income from operations
|
2,431
|
|
|
4,230
|
|
|
6,066
|
|
|
5,259
|
|
||||
Interest and other income (expense), net
|
(73
|
)
|
|
71
|
|
|
23
|
|
|
125
|
|
||||
Income before provision for income taxes
|
2,358
|
|
|
4,301
|
|
|
6,089
|
|
|
5,384
|
|
||||
Provision for income taxes
|
983
|
|
|
1,714
|
|
|
2,363
|
|
|
2,127
|
|
||||
Net income
|
$
|
1,375
|
|
|
$
|
2,587
|
|
|
$
|
3,726
|
|
|
$
|
3,257
|
|
Net income per share-basic
|
$
|
0.04
|
|
|
$
|
0.08
|
|
|
$
|
0.11
|
|
|
$
|
0.10
|
|
Net income per share-diluted
|
$
|
0.04
|
|
|
$
|
0.08
|
|
|
$
|
0.11
|
|
|
$
|
0.10
|
|
Weighted average shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic
|
33,390
|
|
|
33,003
|
|
|
33,377
|
|
|
33,093
|
|
||||
Diluted
|
34,316
|
|
|
33,981
|
|
|
34,329
|
|
|
34,039
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2012
|
|
2011
|
|
2012
|
|
2011
|
||||||||
Net income
|
$
|
1,375
|
|
|
$
|
2,587
|
|
|
$
|
3,726
|
|
|
$
|
3,257
|
|
Other comprehensive income, net of tax:
|
|
|
|
|
|
|
|
||||||||
Unrealized loss on securities:
|
|
|
|
|
|
|
|
||||||||
Unrealized holding losses arising during the period
|
(3
|
)
|
|
—
|
|
|
(1
|
)
|
|
—
|
|
||||
Changes in fair value of foreign currency forward hedges
|
65
|
|
|
—
|
|
|
65
|
|
|
—
|
|
||||
Foreign currency translation adjustment
|
(16
|
)
|
|
—
|
|
|
(16
|
)
|
|
—
|
|
||||
Other comprehensive income
|
46
|
|
|
—
|
|
|
48
|
|
|
—
|
|
||||
Comprehensive income
|
$
|
1,421
|
|
|
$
|
2,587
|
|
|
$
|
3,774
|
|
|
$
|
3,257
|
|
|
Six Months Ended June 30,
|
||||||
|
2012
|
|
2011
|
||||
Cash flows from operating activities:
|
|
|
|
|
|
||
Net income
|
$
|
3,726
|
|
|
$
|
3,257
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
|
|
||
Depreciation and amortization
|
5,333
|
|
|
3,794
|
|
||
Loss on disposal of fixed assets
|
19
|
|
|
—
|
|
||
Provision for (recovery of) receivable allowance
|
335
|
|
|
(43
|
)
|
||
Share-based compensation expense
|
4,420
|
|
|
4,843
|
|
||
Income tax benefits from employee stock plans
|
(156
|
)
|
|
2,303
|
|
||
Excess tax benefits from employee stock plans
|
(901
|
)
|
|
(2,517
|
)
|
||
Provision for excess and obsolete inventories
|
254
|
|
|
865
|
|
||
Foreign currency remeasurement loss
|
(23
|
)
|
|
(8
|
)
|
||
Deferred income taxes
|
(535
|
)
|
|
(491
|
)
|
||
Changes in operating assets and liabilities:
|
|
|
|
|
|
||
Accounts receivable, net
|
(287
|
)
|
|
(384
|
)
|
||
Inventories
|
4,409
|
|
|
(8,462
|
)
|
||
Prepaid expenses
|
(1,114
|
)
|
|
1,391
|
|
||
Other current assets
|
799
|
|
|
(288
|
)
|
||
Net investment in sales-type leases
|
(780
|
)
|
|
710
|
|
||
Other assets
|
(27
|
)
|
|
215
|
|
||
Accounts payable
|
(817
|
)
|
|
1,138
|
|
||
Accrued compensation
|
5,995
|
|
|
391
|
|
||
Accrued liabilities
|
(3,320
|
)
|
|
(1,260
|
)
|
||
Deferred service revenue
|
449
|
|
|
2,278
|
|
||
Deferred gross profit
|
268
|
|
|
(419
|
)
|
||
Other long-term liabilities
|
711
|
|
|
(50
|
)
|
||
Net cash provided by operating activities
|
18,758
|
|
|
7,263
|
|
||
Cash flows from investing activities:
|
|
|
|
|
|||
Maturities of short-term investments
|
8,122
|
|
|
8,143
|
|
||
Acquisition of intangible assets and intellectual property
|
(249
|
)
|
|
(69
|
)
|
||
Software development for external use
|
(1,414
|
)
|
|
(3,088
|
)
|
||
Purchases of property and equipment
|
(4,087
|
)
|
|
(4,764
|
)
|
||
Business acquisition, net of cash acquired
|
(156,312
|
)
|
|
—
|
|
||
Net cash (used in) provided by investing activities
|
(153,940
|
)
|
|
222
|
|
||
Cash flows from financing activities:
|
|
|
|
|
|
||
Proceeds from issuance of common stock under employee stock purchase and stock option plans
|
3,627
|
|
|
3,613
|
|
||
Stock repurchases
|
(7,060
|
)
|
|
(8,000
|
)
|
||
Excess tax benefits from employee stock plans
|
901
|
|
|
2,517
|
|
||
Net cash used in financing activities
|
(2,532
|
)
|
|
(1,870
|
)
|
||
Effect of exchange rate changes on cash and cash equivalents
|
23
|
|
|
8
|
|
||
Net (decrease) increase in cash and cash equivalents
|
(137,691
|
)
|
|
5,623
|
|
||
Cash and cash equivalents at beginning of period
|
191,762
|
|
|
175,635
|
|
||
Cash and cash equivalents at end of period
|
$
|
54,071
|
|
|
$
|
181,258
|
|
Supplemental disclosure of non-cash operating activity:
|
|
|
|
|
|
||
Acquisition consideration accrued but not paid
|
$
|
(1,833
|
)
|
|
$
|
—
|
|
Satisfaction of acquired legal contingency with indemnification asset
|
—
|
|
|
(1,200
|
)
|
Note 1.
|
Organization and Summary of Significant Accounting Policies
|
•
|
Products
— Software-enabled equipment that manages and regulates the storage and dispensing of pharmaceuticals, consumable blister cards and packaging equipment and other medical supplies.
|
•
|
Software
— Additional software applications that enable incremental functionality of our equipment.
|
•
|
Installation
— Installation of equipment as integrated systems at customers’ sites.
|
•
|
Post-installation technical support
— Phone support, on-site service, parts and access to unspecified software upgrades and enhancements, if and when available.
|
•
|
Professional services
— Other customer services, such as training and consulting.
|
Note 2.
|
Net Income Per Share
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
|
|||||||||||
|
2012
|
|
2011
|
|
2012
|
|
2011
|
||||||||
Basic:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net income
|
$
|
1,375
|
|
|
$
|
2,587
|
|
|
$
|
3,726
|
|
|
$
|
3,257
|
|
Weighted average shares outstanding — basic
|
33,390
|
|
|
33,003
|
|
|
33,377
|
|
|
33,093
|
|
||||
Net income per share — basic
|
$
|
0.04
|
|
|
$
|
0.08
|
|
|
$
|
0.11
|
|
|
$
|
0.10
|
|
Diluted:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net income
|
$
|
1,375
|
|
|
$
|
2,587
|
|
|
$
|
3,726
|
|
|
$
|
3,257
|
|
Weighted average shares outstanding — basic
|
33,390
|
|
|
33,003
|
|
|
33,377
|
|
|
33,093
|
|
||||
Add: Dilutive effect of employee stock plans
|
926
|
|
|
978
|
|
|
952
|
|
|
946
|
|
||||
Weighted average shares outstanding — diluted
|
34,316
|
|
|
33,981
|
|
|
34,329
|
|
|
34,039
|
|
||||
Net income per share — diluted
|
$
|
0.04
|
|
|
$
|
0.08
|
|
|
$
|
0.11
|
|
|
$
|
0.10
|
|
Note 3.
|
Cash and Cash Equivalents, Short-term Investments and Fair Value of Financial Instruments
|
|
June 30, 2012
|
|
|
||||||||||||||||||||||
|
Amortized
Cost
|
|
Unrealized
Gains
|
|
Unrealized
Losses
|
|
Fair Value
|
|
Cash / Cash
Equivalents
|
|
Short-term
Investments
|
|
Security
Classification (1)
|
||||||||||||
Cash
|
$
|
20,443
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
20,443
|
|
|
$
|
20,443
|
|
|
$
|
—
|
|
|
N/A
|
Money market funds
|
33,628
|
|
|
—
|
|
|
—
|
|
|
33,628
|
|
|
33,628
|
|
|
—
|
|
|
Available for sale
|
||||||
Total cash, cash equivalents and short-term investments
|
$
|
54,071
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
54,071
|
|
|
$
|
54,071
|
|
|
$
|
—
|
|
|
|
|
December 31, 2011
|
|
|
||||||||||||||||||||||
|
Amortized
Cost
|
|
Unrealized
Gains
|
|
Unrealized
Losses
|
|
Fair Value
|
|
Cash / Cash
Equivalents
|
|
Short-term
Investments
|
|
Security
Classification
|
||||||||||||
Cash
|
$
|
14,452
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
14,452
|
|
|
$
|
14,452
|
|
|
$
|
—
|
|
|
N/A
|
Money market funds
|
177,310
|
|
|
—
|
|
|
—
|
|
|
177,310
|
|
|
177,310
|
|
|
—
|
|
|
Available for sale
|
||||||
Non-U.S. government securities
|
8,106
|
|
|
1
|
|
|
—
|
|
|
8,107
|
|
|
—
|
|
|
8,107
|
|
|
Available for sale
|
||||||
Total cash, cash equivalents and short-term investments
|
$
|
199,868
|
|
|
$
|
1
|
|
|
$
|
—
|
|
|
$
|
199,869
|
|
|
$
|
191,762
|
|
|
$
|
8,107
|
|
|
|
|
|
|
|
|
|
Quoted Prices in Active
Markets for Identical
Instruments
(Level 1)
|
|
Significant Other
Observable Inputs
(Level 2)
|
|
Significant
Unobservable
Inputs
(Level 3)
|
|
Total Fair
Value
|
|||||||
At June 30, 2012
|
|
|
|
|
|
|
|
|
|
|
|
|||
Money market funds
|
$
|
33,628
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
33,628
|
|
Total
|
$
|
33,628
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
33,628
|
|
At December 31, 2011
|
|
|
|
|
|
|
|
|
|
|
|
|||
Money market funds
|
$
|
177,310
|
|
|
—
|
|
|
—
|
|
|
$
|
177,310
|
|
|
Non U.S. Government securities
|
—
|
|
|
$
|
8,107
|
|
|
—
|
|
|
8,107
|
|
||
Total
|
$
|
177,310
|
|
|
$
|
8,107
|
|
|
—
|
|
|
$
|
185,417
|
|
Note 4.
|
Inventories
|
|
June 30,
2012 |
|
December 31,
2011 |
||||
Raw materials
|
$
|
11,310
|
|
|
$
|
7,666
|
|
Work in process
|
585
|
|
|
14
|
|
||
Finished goods
|
13,275
|
|
|
10,427
|
|
||
Total
|
$
|
25,170
|
|
|
$
|
18,107
|
|
Note 5.
|
Property and Equipment
|
|
June 30,
2012 |
|
December 31,
2011 |
||||
Equipment
|
$
|
35,322
|
|
|
$
|
25,101
|
|
Furniture and fixtures
|
2,256
|
|
|
1,811
|
|
||
Leasehold improvements
|
4,196
|
|
|
3,692
|
|
||
Purchased software
|
21,264
|
|
|
20,641
|
|
||
Capital in process
|
2,391
|
|
|
2,283
|
|
||
|
65,429
|
|
|
53,528
|
|
||
Accumulated depreciation and amortization
|
(36,464
|
)
|
|
(36,222
|
)
|
||
Property and equipment, net
|
$
|
28,965
|
|
|
$
|
17,306
|
|
Note 6.
|
Net Investment in Sales-Type Leases
|
|
June 30,
2012 |
|
December 31,
2011 |
||||
Net minimum lease payments to be received
|
$
|
15,328
|
|
|
$
|
15,063
|
|
Less unearned interest income portion
|
1,113
|
|
|
1,229
|
|
||
Net investment in sales-type leases
|
14,215
|
|
|
13,834
|
|
||
Less current portion(1)
|
4,389
|
|
|
5,049
|
|
||
Non-current net investment in sales-type leases(2)
|
$
|
9,826
|
|
|
$
|
8,785
|
|
|
|
|
|
|
2012 (remaining six months)
|
$
|
2,559
|
|
|
2013
|
4,601
|
|
|
|
2014
|
3,512
|
|
|
|
2015
|
2,516
|
|
|
|
2016
|
1,573
|
|
|
|
2017
|
567
|
|
|
|
Thereafter
|
—
|
|
|
|
Total
|
$
|
15,328
|
|
|
|
Allowance for Credit Losses
|
|
Recorded Investment
in Sales-type Leases Gross
|
|
Recorded Investment
in Sales-type Leases Net
|
||||||
Credit loss disclosure for June 30, 2012 :
|
|
|
|
|
|
|
|
|
|||
Accounts individually evaluated for impairment
|
$
|
544
|
|
|
$
|
544
|
|
|
$
|
—
|
|
Accounts collectively evaluated for impairment
|
115
|
|
|
14,330
|
|
|
14,215
|
|
|||
Ending balances: June 30, 2012
|
$
|
659
|
|
|
$
|
14,874
|
|
|
$
|
14,215
|
|
Credit loss disclosure for December 31, 2011 :
|
|
|
|
|
|
|
|
|
|||
Accounts individually evaluated for impairment
|
$
|
178
|
|
|
$
|
178
|
|
|
$
|
—
|
|
Accounts collectively evaluated for impairment
|
106
|
|
|
13,940
|
|
|
13,834
|
|
|||
Ending balances: December 31, 2011
|
$
|
284
|
|
|
$
|
14,118
|
|
|
$
|
13,834
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2012
|
|
2011
|
|
2012
|
|
2011
|
||||||||
Allowance for credit losses, beginning of period
|
$
|
257
|
|
|
$
|
380
|
|
|
$
|
284
|
|
|
$
|
411
|
|
Current period provision (reversal)
|
422
|
|
|
(5
|
)
|
|
422
|
|
|
(9
|
)
|
||||
Direct write-downs charged against the allowance
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
Recoveries of amounts previously charged off
|
(20
|
)
|
|
(22
|
)
|
|
(47
|
)
|
|
(49
|
)
|
||||
Allowance for credit losses, end of period
|
$
|
659
|
|
|
$
|
353
|
|
|
$
|
659
|
|
|
$
|
353
|
|
Note 7.
|
Goodwill and Other Intangible Assets
|
|
Goodwill at December 31, 2011
|
|
Goodwill acquired
|
|
Other adjustments
|
|
Goodwill at June 30, 2012
|
||||||||
Reporting units:
|
|
|
|
|
|
|
|
||||||||
Acute Care
|
$
|
28,543
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
28,543
|
|
Non-Acute Care
|
—
|
|
|
84,491
|
|
|
—
|
|
|
84,491
|
|
||||
Total
|
$
|
28,543
|
|
|
$
|
84,491
|
|
|
$
|
—
|
|
|
$
|
113,034
|
|
|
June 30, 2012
|
|
December 31, 2011
|
|
|
||||||||||||||||||||
|
Gross
|
|
|
|
Net
|
|
Gross
|
|
|
|
Net
|
|
|
||||||||||||
|
Carrying
Amount
|
|
Accumulated
Amortization
|
|
Carrying
Amount
|
|
Carrying
Amount
|
|
Accumulated
Amortization
|
|
Carrying
Amount
|
|
Amortization
Life
|
||||||||||||
Finite-lived intangibles:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Customer relationships
|
$
|
54,330
|
|
|
$
|
2,003
|
|
|
$
|
52,327
|
|
|
$
|
4,230
|
|
|
$
|
1,591
|
|
|
$
|
2,639
|
|
|
5-30 years
|
Acquired technology
|
27,580
|
|
|
393
|
|
|
27,187
|
|
|
980
|
|
|
175
|
|
|
805
|
|
|
3-20 years
|
||||||
Patents
|
1,138
|
|
|
210
|
|
|
928
|
|
|
889
|
|
|
190
|
|
|
699
|
|
|
20 years
|
||||||
Trade name
|
6,890
|
|
|
115
|
|
|
6,775
|
|
|
90
|
|
|
37
|
|
|
53
|
|
|
3-12 years
|
||||||
Non-compete agreements
|
60
|
|
|
35
|
|
|
25
|
|
|
60
|
|
|
25
|
|
|
35
|
|
|
3 years
|
||||||
Total finite-lived intangibles
|
$
|
89,998
|
|
|
$
|
2,756
|
|
|
$
|
87,242
|
|
|
$
|
6,249
|
|
|
$
|
2,018
|
|
|
$
|
4,231
|
|
|
|
2012 (remaining six months)
|
$
|
2,124
|
|
2013
|
4,235
|
|
|
2014
|
4,195
|
|
|
2015
|
4,172
|
|
|
2016
|
3,821
|
|
|
2017
|
3,786
|
|
|
Thereafter
|
64,909
|
|
|
Total
|
$
|
87,242
|
|
Note 8.
|
Accrued Liabilities
|
|
June 30,
2012 |
|
December 31,
2011 |
||||
Advance payments from customers
|
$
|
2,805
|
|
|
$
|
3,390
|
|
Accrued Group Purchasing Organization (GPO) fees
|
2,055
|
|
|
2,437
|
|
||
Acquisition consideration payable
|
1,833
|
|
|
—
|
|
||
Rebates and lease buyouts
|
1,125
|
|
|
1,748
|
|
||
Taxes payable
|
527
|
|
|
925
|
|
||
Other
|
1,611
|
|
|
401
|
|
||
Total
|
$
|
9,956
|
|
|
$
|
8,901
|
|
Note 9.
|
Deferred Gross Profit
|
|
June 30,
2012 |
|
December 31,
2011 |
||||
Sales of medication and supply dispensing systems
and packaging equipment,
which have been delivered and invoiced but not yet installed
|
$
|
23,463
|
|
|
$
|
24,181
|
|
Cost of revenues, excluding installation costs
|
(8,985
|
)
|
|
(9,971
|
)
|
||
Deferred gross profit
|
$
|
14,478
|
|
|
$
|
14,210
|
|
Note 10.
|
Commitments
|
2012 (remaining six months)
|
$
|
2,978
|
|
2013
|
5,154
|
|
|
2014
|
5,272
|
|
|
2015
|
5,183
|
|
|
2016
|
4,898
|
|
|
2017
|
4,206
|
|
|
Thereafter
|
20,430
|
|
|
Total
|
$
|
48,121
|
|
Note 11.
|
Contingencies
|
Note 12.
|
Stockholders’ Equity
|
Note 13.
|
Stock Option Plans and Share-Based Compensation
|
Options:
|
|
Number of Shares
|
|
Weighted-
Average
Exercise Price
|
|||
|
|
(in thousands)
|
|
|
|||
Outstanding at December 31, 2011
|
|
4,693
|
|
|
$
|
13.36
|
|
Granted
|
|
390
|
|
|
$
|
15.28
|
|
Exercised
|
|
(219
|
)
|
|
$
|
9.17
|
|
Forfeited
|
|
(44
|
)
|
|
$
|
13.23
|
|
Expired
|
|
(81
|
)
|
|
$
|
21.65
|
|
Outstanding at June 30, 2012
|
|
4,739
|
|
|
$
|
13.57
|
|
Exercisable at June 30, 2012
|
|
3,565
|
|
|
$
|
13.46
|
|
|
Restricted Stock
|
|
Restricted Stock Units
|
||||||||||
|
|
|
Weighted -
|
|
|
|
Weighted -
|
||||||
|
Number of
Shares
|
|
Average
Grant Date
Fair Value Per
Share
|
|
Number of
Shares
|
|
Average
Grant Date
Fair Value Per
Share
|
||||||
|
(in thousands)
|
|
|
|
(in thousands)
|
|
|
||||||
Non-vested, December 31, 2011
|
68
|
|
|
$
|
14.71
|
|
|
287
|
|
|
$
|
13.03
|
|
Granted
|
67
|
|
|
$
|
14.19
|
|
|
197
|
|
|
$
|
14.82
|
|
Vested
|
(68
|
)
|
|
$
|
14.71
|
|
|
(73
|
)
|
|
$
|
12.81
|
|
Forfeited
|
—
|
|
|
—
|
|
|
(13
|
)
|
|
$
|
14.51
|
|
|
Non-vested, June 30, 2012
|
67
|
|
|
$
|
14.19
|
|
|
398
|
|
|
$
|
13.90
|
|
Percentile Placement of
Our Total Shareholder Return |
% of PSUs Eligible for Time-
Based Vesting |
Below the 35th percentile
|
—%
|
At least the 35th percentile, but below the 50th percentile
|
50%
|
At least the 50th percentile, but below the 65th percentile
|
100%
|
At least the 65th percentile, but below the 75th percentile (1)
|
110% to 119%
|
At or above the 75th percentile
|
120%
|
|
|
|
|
|
Percentile Placement of
Our Total Shareholder Return |
% of PSUs Eligible for Time-
Based Vesting |
Below the 35th percentile
|
—%
|
At least the 35th percentile, but below the 50th percentile
|
50%
|
At least the 50th percentile
|
100%
|
|
|
|
Weighted -
Average
Grant Date
Fair Value Per
|
|||
Performance-based Stock Units
|
Number of Shares
|
|
Share
|
|||
|
(in thousands)
|
|
|
|
||
Non-vested, December 31, 2011
|
100
|
|
|
$
|
11.15
|
|
Granted
|
133
|
|
|
$
|
10.94
|
|
Vested
|
(45
|
)
|
|
$
|
11.15
|
|
Forfeited
|
—
|
|
|
—
|
|
|
Non-vested, June 30, 2012
|
188
|
|
|
$
|
11.00
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2012
|
|
2011
|
|
2012
|
|
2011
|
||||||||
Cost of product and service revenues
|
$
|
233
|
|
|
$
|
383
|
|
|
$
|
501
|
|
|
$
|
750
|
|
Research and development expenses
|
211
|
|
|
345
|
|
|
454
|
|
|
672
|
|
||||
Selling, general and administrative expenses
|
1,769
|
|
|
1,723
|
|
|
3,465
|
|
|
3,421
|
|
||||
Total share-based compensation expenses
|
$
|
2,213
|
|
|
$
|
2,451
|
|
|
$
|
4,420
|
|
|
$
|
4,843
|
|
Note 14.
|
Business Acquisition
|
|
|
Fair value acquired
|
|
|
|
Cash including restricted cash
|
|
$
|
2,000
|
|
|
Accounts receivable
|
|
7,403
|
|
|
|
Inventory
|
|
11,726
|
|
|
|
Deferred tax assets and other current assets
|
|
2,864
|
|
|
|
Total current assets
|
|
23,993
|
|
|
|
Property and equipment
|
|
11,088
|
|
|
|
Intangibles
|
|
83,500
|
|
|
|
Goodwill
|
|
84,491
|
|
|
|
Other non-current assets
|
|
244
|
|
|
|
Total assets
|
|
203,316
|
|
|
|
Current liabilities
|
|
(8,046
|
)
|
|
|
Non-current deferred tax liabilities
|
|
(33,898
|
)
|
|
|
Other non-current liabilities
|
|
(1,227
|
)
|
|
|
Net assets acquired
|
|
$
|
160,145
|
|
|
|
|
|
|
||
Cash consideration, fair value
|
|
$
|
160,145
|
|
|
|
|
|
|
|
|
Fair value acquired
|
|
|
Useful Life (years)
|
|
First year amortization expense
|
|
|
||
Trade name
|
|
$
|
6,800
|
|
|
12
|
|
$
|
567
|
|
|
Customer relationships
|
|
50,100
|
|
|
28 to 30
|
|
1,693
|
|
|
||
Acquired technology
|
|
26,600
|
|
|
20
|
|
1,330
|
|
|
||
Intangibles acquired
|
|
$
|
83,500
|
|
|
|
|
$
|
3,590
|
|
|
|
|
|
|
|
|
|
|
||||
Weighted avg. life of intangibles
|
|
|
|
25.11
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2012
|
|
2011
|
|
2012
|
|
2011
|
||||||||
Revenues
|
$
|
85,204
|
|
|
$
|
80,798
|
|
|
$
|
168,270
|
|
|
$
|
157,247
|
|
Net income
|
$
|
4,110
|
|
|
$
|
3,874
|
|
|
$
|
6,595
|
|
|
$
|
6,056
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30,
|
|
Three Months Ended June 30,
|
|
||||||||||||||||
|
2012
|
|
2011
|
|
||||||||||||||||
|
Acute Care
|
|
Non-Acute Care (1)
|
|
Total
|
|
Acute Care
|
|
Total
|
|
||||||||||
Net revenues from external customers
|
$
|
66,528
|
|
|
$
|
8,856
|
|
|
$
|
75,384
|
|
|
$
|
61,005
|
|
|
$
|
61,005
|
|
|
Cost of revenues
|
29,158
|
|
|
6,850
|
|
|
36,008
|
|
|
27,198
|
|
|
27,198
|
|
|
|||||
Gross profit
|
$
|
37,370
|
|
|
$
|
2,006
|
|
|
$
|
39,376
|
|
|
$
|
33,807
|
|
|
$
|
33,807
|
|
|
Gross margin %
|
56.2
|
%
|
|
22.7
|
%
|
|
52.2
|
%
|
|
55.4
|
%
|
|
55.4
|
%
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Operating expenses
|
33,458
|
|
|
3,487
|
|
|
36,945
|
|
|
29,577
|
|
|
29,577
|
|
|
|||||
Income from operations
|
$
|
3,912
|
|
|
$
|
(1,481
|
)
|
|
$
|
2,431
|
|
|
$
|
4,230
|
|
|
$
|
4,230
|
|
|
Operating margin %
|
5.9
|
%
|
|
(16.7
|
)%
|
|
3.2
|
%
|
|
6.9
|
%
|
|
6.9
|
%
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Interest and other income (expense), net
|
|
|
|
|
(73
|
)
|
|
|
|
71
|
|
|
||||||||
Income before provision for income taxes
|
|
|
|
|
2,358
|
|
|
|
|
4,301
|
|
|
||||||||
Provision for income taxes
|
|
|
|
|
983
|
|
|
|
|
1,714
|
|
|
||||||||
Net income
|
|
|
|
|
$
|
1,375
|
|
|
|
|
$
|
2,587
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
(1) Non-Acute Care segment included from the May 21, 2012 acquisition of MTS
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30,
|
|
Six Months Ended June 30,
|
|
||||||||||||||||
|
2012
|
|
2011
|
|
||||||||||||||||
|
Acute Care
|
|
Non-Acute Care (1)
|
|
Total
|
|
Acute Care
|
|
Total
|
|
||||||||||
Net revenues from external customers
|
$
|
130,671
|
|
|
$
|
8,856
|
|
|
$
|
139,527
|
|
|
$
|
118,165
|
|
|
$
|
118,165
|
|
|
Cost of revenues
|
57,552
|
|
|
6,850
|
|
|
64,402
|
|
|
52,708
|
|
|
52,708
|
|
|
|||||
Gross profit
|
$
|
73,119
|
|
|
$
|
2,006
|
|
|
$
|
75,125
|
|
|
$
|
65,457
|
|
|
$
|
65,457
|
|
|
Gross margin %
|
56.0
|
%
|
|
22.7
|
%
|
|
53.8
|
%
|
|
55.4
|
%
|
|
55.4
|
%
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Operating expenses
|
65,572
|
|
|
3,487
|
|
|
69,059
|
|
|
60,198
|
|
|
60,198
|
|
|
|||||
Income from operations
|
$
|
7,547
|
|
|
$
|
(1,481
|
)
|
|
$
|
6,066
|
|
|
$
|
5,259
|
|
|
$
|
5,259
|
|
|
Operating margin %
|
5.8
|
%
|
|
(16.7
|
)%
|
|
4.3
|
%
|
|
4.5
|
%
|
|
4.5
|
%
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Interest and other income (expense), net
|
|
|
|
|
23
|
|
|
|
|
125
|
|
|
||||||||
Income before provision for income taxes
|
|
|
|
|
6,089
|
|
|
|
|
5,384
|
|
|
||||||||
Provision for income taxes
|
|
|
|
|
2,363
|
|
|
|
|
2,127
|
|
|
||||||||
Net income
|
|
|
|
|
$
|
3,726
|
|
|
|
|
$
|
3,257
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
(1) Non-Acute Care segment included from the May 21, 2012 acquisition of MTS
|
|
|
|
|
|
|
|
|
|
|
Item 2.
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
•
|
the extent and timing of future revenues, including the amounts of our current backlog, which represent firm orders that have not completed installation and therefore have not been recognized as revenue;
|
•
|
our ability to conduct acquisitions for strategic value, including our acquisition of MTS, and successfully integrate each one into our operations;
|
•
|
the size and/or growth of our market or market-share;
|
•
|
the opportunity presented by new products or emerging markets;
|
•
|
our expectations regarding our future backlog levels;
|
•
|
the operating margins or earnings per share goals we may set;
|
•
|
our ability to align our cost structure and headcount with our current business expectations;
|
•
|
our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; and
|
•
|
our ability to generate cash from operations and our estimates regarding the sufficiency of our cash resources.
|
•
|
We have continued to differentiate ourselves through a strategy intended to create the best customer experience in healthcare;
|
•
|
We have delivered industry-leading products with differentiated product features that are designed to appeal to nurses and pharmacists, such as our G4 platform, the Savvy
TM
Mobile Medication System, SinglePointe
TM
, Anywhere RN
TM
and OnDemand;
|
•
|
Through acquisitions, we have broadened our medication control product line to address the growing need for medication management across the continuum of care beyond hospitals; and
|
•
|
The market environment of increased patient safety awareness and increased regulatory control has driven our solutions to be a high priority in customers’ capital budgets.
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||||||||||||||
|
2012
|
|
2011
|
|
2012
|
|
2011
|
||||||||||||||||||||
|
$
|
|
% of
Revenue
|
|
$
|
|
% of
Revenue
|
|
$
|
|
% of
Revenue
|
|
$
|
|
% of
Revenue
|
||||||||||||
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Product revenue
|
$
|
59,269
|
|
|
78.6
|
%
|
|
$
|
46,218
|
|
|
75.8
|
%
|
|
$
|
107,793
|
|
|
77.3
|
%
|
|
$
|
88,793
|
|
|
75.1
|
%
|
Service and other revenues
|
16,115
|
|
|
21.4
|
%
|
|
14,787
|
|
|
24.2
|
%
|
|
31,734
|
|
|
22.7
|
%
|
|
29,372
|
|
|
24.9
|
%
|
||||
Total revenues
|
75,384
|
|
|
100.0
|
%
|
|
61,005
|
|
|
100.0
|
%
|
|
139,527
|
|
|
100.0
|
%
|
|
118,165
|
|
|
100.0
|
%
|
||||
Cost of revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of product revenues
|
28,600
|
|
|
38.0
|
%
|
|
19,730
|
|
|
32.4
|
%
|
|
48,896
|
|
|
35.0
|
%
|
|
37,566
|
|
|
31.8
|
%
|
||||
Cost of service and other revenues
|
7,408
|
|
|
9.8
|
%
|
|
7,468
|
|
|
12.2
|
%
|
|
15,506
|
|
|
11.1
|
%
|
|
15,142
|
|
|
12.8
|
%
|
||||
Total cost of revenues
|
36,008
|
|
|
47.8
|
%
|
|
27,198
|
|
|
44.6
|
%
|
|
64,402
|
|
|
46.1
|
%
|
|
52,708
|
|
|
44.6
|
%
|
||||
Gross profit
|
39,376
|
|
|
52.2
|
%
|
|
33,807
|
|
|
55.4
|
%
|
|
75,125
|
|
|
53.9
|
%
|
|
65,457
|
|
|
55.4
|
%
|
||||
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development
|
5,499
|
|
|
7.3
|
%
|
|
5,280
|
|
|
8.7
|
%
|
|
11,993
|
|
|
8.6
|
%
|
|
10,120
|
|
|
8.5
|
%
|
||||
Selling, general and administrative
|
31,446
|
|
|
41.7
|
%
|
|
24,297
|
|
|
39.8
|
%
|
|
57,066
|
|
|
40.9
|
%
|
|
50,078
|
|
|
42.4
|
%
|
||||
Total operating expenses
|
36,945
|
|
|
49.0
|
%
|
|
29,577
|
|
|
48.5
|
%
|
|
69,059
|
|
|
49.5
|
%
|
|
60,198
|
|
|
50.9
|
%
|
||||
Income from operations
|
2,431
|
|
|
3.2
|
%
|
|
4,230
|
|
|
6.9
|
%
|
|
6,066
|
|
|
4.4
|
%
|
|
5,259
|
|
|
4.5
|
%
|
||||
Interest and other income (expense), net
|
(73
|
)
|
|
(0.1
|
)%
|
|
71
|
|
|
0.1
|
%
|
|
23
|
|
|
—
|
|
|
125
|
|
|
0.1
|
%
|
||||
Income before provision for income taxes
|
2,358
|
|
|
3.1
|
%
|
|
4,301
|
|
|
7.0
|
%
|
|
6,089
|
|
|
4.4
|
%
|
|
5,384
|
|
|
4.6
|
%
|
||||
Provision for income taxes
|
983
|
|
|
1.3
|
%
|
|
1,714
|
|
|
2.8
|
%
|
|
2,363
|
|
|
1.7
|
%
|
|
2,127
|
|
|
1.8
|
%
|
||||
Net income
|
$
|
1,375
|
|
|
1.8
|
%
|
|
$
|
2,587
|
|
|
4.2
|
%
|
|
$
|
3,726
|
|
|
2.7
|
%
|
|
$
|
3,257
|
|
|
2.8
|
%
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||||||||
|
2012
|
|
2011
|
|
% Change
|
|
2012
|
|
2011
|
|
% Change
|
||||||||||
Product revenues
|
$
|
59,269
|
|
|
$
|
46,218
|
|
|
28.2
|
%
|
|
$
|
107,793
|
|
|
$
|
88,793
|
|
|
21.4
|
%
|
Cost of product revenues
|
28,600
|
|
|
19,730
|
|
|
45.0
|
%
|
|
48,896
|
|
|
37,566
|
|
|
30.2
|
%
|
||||
Gross profit
|
$
|
30,669
|
|
|
$
|
26,488
|
|
|
15.8
|
%
|
|
$
|
58,897
|
|
|
$
|
51,227
|
|
|
15.0
|
%
|
Gross margin
|
51.7
|
%
|
|
57.3
|
%
|
|
|
|
54.6
|
%
|
|
57.7
|
%
|
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||||||||
|
2012
|
|
2011
|
|
% Change
|
|
2012
|
|
2011
|
|
% Change
|
||||||||||
|
|
|
|
|
|
|
|
||||||||||||||
Service and other revenues
|
$
|
16,115
|
|
|
$
|
14,787
|
|
|
9.0
|
%
|
|
$
|
31,734
|
|
|
$
|
29,372
|
|
|
8.0
|
%
|
Cost of service and other revenues
|
7,408
|
|
|
7,468
|
|
|
(0.8
|
)%
|
|
15,506
|
|
|
15,142
|
|
|
2.4
|
%
|
||||
Gross profit
|
$
|
8,707
|
|
|
$
|
7,319
|
|
|
19.0
|
%
|
|
$
|
16,228
|
|
|
$
|
14,230
|
|
|
14.0
|
%
|
Gross margin
|
54.0
|
%
|
|
49.5
|
%
|
|
|
|
51.1
|
%
|
|
48.4
|
%
|
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||||||||
|
2012
|
|
2011
|
|
% Change
|
|
2012
|
|
2011
|
|
% Change
|
||||||||||
Research and development
|
$
|
5,499
|
|
|
$
|
5,280
|
|
|
4.1
|
%
|
|
$
|
11,993
|
|
|
$
|
10,120
|
|
|
18.5
|
%
|
Selling, general and administrative
|
31,446
|
|
|
24,297
|
|
|
29.4
|
%
|
|
57,066
|
|
|
50,078
|
|
|
14.0
|
%
|
||||
Total operating expenses
|
$
|
36,945
|
|
|
$
|
29,577
|
|
|
24.9
|
%
|
|
$
|
69,059
|
|
|
$
|
60,198
|
|
|
14.7
|
%
|
|
Six Months Ended June 30,
|
||||||
|
2012
|
|
2011
|
||||
Net cash provided by operating activities
|
$
|
18,758
|
|
|
$
|
7,263
|
|
Net cash (used in) provided by investing activities
|
(153,940
|
)
|
|
222
|
|
||
Net cash used in financing activities
|
(2,532
|
)
|
|
(1,870
|
)
|
||
Effect of exchange rate changes on cash and cash equivalents
|
23
|
|
|
8
|
|
||
Net (decrease) increase in cash and cash equivalents
|
$
|
(137,691
|
)
|
|
$
|
5,623
|
|
|
Total
|
|
Less than one
year
|
|
One to three
years
|
|
Three to five
years
|
|
More than
five years
|
||||||||||
Operating leases (1) (2) (3) (4)
|
$
|
48,121
|
|
|
$
|
5,486
|
|
|
$
|
10,591
|
|
|
$
|
9,549
|
|
|
$
|
22,495
|
|
Commitments to contract manufacturers and suppliers (5)
|
7,310
|
|
|
7,310
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Total (6)
|
$
|
55,431
|
|
|
$
|
12,796
|
|
|
$
|
10,591
|
|
|
$
|
9,549
|
|
|
$
|
22,495
|
|
|
|
|
|
|
Item 3.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
Item 4.
|
CONTROLS AND PROCEDURES
|
Item 1.
|
LEGAL PROCEEDINGS
|
Item 1A.
|
RISK FACTORS
|
•
|
certain competitors may develop new features or capabilities for their products not previously offered that could compete directly with our products;
|
•
|
competitive pressures could result in increased price competition for our products and services, fewer customer orders and reduced gross margins, any of which could harm our business;
|
•
|
current and potential competitors may make strategic acquisitions or establish cooperative relationships among
|
•
|
our competitors may develop, license or incorporate new or emerging technologies or devote greater resources to the development, promotion and sale of their products and services than we do;
|
•
|
certain competitors have greater brand name recognition and a more extensive installed base of medication and supply dispensing systems or other products and services than we do, and such advantages could be used to increase their market share;
|
•
|
certain competitors may have existing business relationships with our current and potential customers, which may cause these customers to purchase medication and supply dispensing systems or automation solutions from these competitors;
|
•
|
other established or emerging companies may enter the medication management and supply chain solutions market; and
|
•
|
our competitors may secure products and services from suppliers on more favorable terms or secure exclusive arrangements with suppliers or buyers that may impede the sales of our products and services.
|
•
|
difficulties in combining previously separate businesses into a single unit;
|
•
|
the substantial costs that may be incurred and the substantial diversion of management’s attention from day-to-day business when evaluating and negotiating such transactions and then integrating an acquired business;
|
•
|
discovery, after completion of the acquisition, of liabilities assumed from the acquired business or of assets acquired that are broader in scope and magnitude or are more difficult to manage than originally assumed;
|
•
|
failure to achieve anticipated benefits such as cost savings and revenue enhancements;
|
•
|
difficulties related to assimilating the products of an acquired business; and
|
•
|
failure to understand and compete effectively in markets in which we have limited previous experience.
|
•
|
inability or failure to expand in long term care markets for medication management and adherence;
|
•
|
inability or failure to effectively coordinate sales and marketing efforts to communicate the capabilities of the combined company;
|
•
|
inability or failure to successfully integrate and harmonize financial reporting and information technology systems;
|
•
|
inability or failure to achieve the expected operational and cost efficiencies; and
|
•
|
loss of key employees.
|
•
|
the difficulty of managing an organization operating in various countries;
|
•
|
growing political sentiment against international outsourcing of production;
|
•
|
reduced protection for intellectual property rights, particularly in jurisdictions that have less developed intellectual property regimes;
|
•
|
changes in foreign regulatory requirements;
|
•
|
the requirement to comply with a variety of international laws and regulations, including labor, import, export, tax, anti-bribery and employment laws and changes in tariff rates;
|
•
|
fluctuations in currency exchange rates and difficulties in repatriating funds from certain countries; and
|
•
|
political unrest, terrorism and the potential for other hostilities in areas in which we have facilities.
|
•
|
our ability to successfully install our products on a timely basis and meet other contractual obligations necessary to recognize revenue;
|
•
|
the size, product mix and timing of orders for our medication and supply dispensing systems, and our medication packaging systems, and their installation and integration;
|
•
|
the overall demand for healthcare medication management and supply chain solutions;
|
•
|
changes in pricing policies by us or our competitors;
|
•
|
the number, timing and significance of product enhancements and new product announcements by us or our competitors;
|
•
|
the timing and significance of any acquisition or business development transactions that we may consider or negotiate and the revenues, costs and earnings that may be associated with these transactions;
|
•
|
the relative proportions of revenues we derive from products and services;
|
•
|
fluctuations in the percentage of sales attributable to our international business;
|
•
|
our customers’ budget cycles;
|
•
|
changes in our operating expenses and our ability to stabilize expenses;
|
•
|
our ability to generate cash from our accounts receivable on a timely basis;
|
•
|
the performance of our products;
|
•
|
changes in our business strategy;
|
•
|
macroeconomic and political conditions, including fluctuations in interest rates, tax increases and availability of credit markets; and
|
•
|
volatility in our stock price and its effect on equity-based compensation expense.
|
•
|
changes in our operating results;
|
•
|
developments in our relationships with corporate customers;
|
•
|
changes in the ratings of our common stock by securities analysts;
|
•
|
announcements by us or our competitors of technological innovations or new products;
|
•
|
announcements by us or our competitors of acquisitions of businesses, products or technologies; or
|
•
|
general economic and market conditions.
|
Item 2.
|
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
|
Period
|
|
Total number of
shares (or units)
purchased
|
|
Average
price paid per
share (or unit),
including
commissions
|
|
Total number
of Shares (or units) purchased
as part of
publicly announced
plans or programs
|
|
Maximum number (or
approximate dollar value)
of shares (or units) that
may yet be
purchased under the
plans or programs
|
||||||
April 1—30, 2012
|
|
244,687
|
|
|
$
|
14.00
|
|
|
244,687
|
|
|
$
|
8.9
|
million
|
May 1—31, 2012
|
|
—
|
|
|
—
|
|
|
—
|
|
|
$
|
8.9
|
million
|
|
June 1—30, 2012
|
|
260,450
|
|
|
$
|
13.95
|
|
|
260,450
|
|
|
$
|
5.3
|
million
|
Total
|
|
505,137
|
|
|
$
|
13.98
|
|
|
505,137
|
|
|
|
Item 3.
|
DEFAULTS UPON SENIOR SECURITIES
|
Item 4.
|
MINE SAFETY DISCLOSURES
|
Item 5.
|
OTHER INFORMATION
|
Item 6.
|
EXHIBITS
|
Exhibit
No.
|
|
Exhibit Title
|
2.1(1)
|
|
Agreement and Plan of Merger, dated as of April 26, 2012, by and among Omnicell, Inc., Mercury Acquisition Corp, MedPak Holdings, Inc. and Excellere Capital Management, LLC.
|
3.1(2)
|
|
Amended and Restated Certificate of Incorporation of Omnicell, Inc.
|
3.2(3)
|
|
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Omnicell, Inc.
|
3.3(4)
|
|
Certificate of Designation of Series A Junior Participating Preferred Stock.
|
3.4(5)
|
|
Bylaws of Omnicell, Inc., as amended.
|
4.1(2)
|
|
Form of Common Stock Certificate.
|
4.2
|
|
Reference is made to Exhibits 3.1, 3.2, 3.3 and 3.4.
|
4.3(6)
|
|
Rights Agreement, dated February 6, 2003, between Omnicell, Inc. and EquiServe Trust Company, N.A.
|
10.1*
|
|
Omnicell, Inc. Amended and Restated Severance Benefit Plan.
|
10.2*
|
|
Offer Letter, dated May 24, 2012, between Omnicell, Inc. and William Shields.
|
10.3*
|
|
Change of Control Agreement, dated May 23, 2012, between Omnicell, Inc. and William Shields and Addendum thereto dated June 24, 2012.
|
10.4*
|
|
Form of Restricted Stock Unit Award Agreement for the 2009 Equity Incentive Plan, as amended.
|
10.5*
|
|
Form of Performance Cash Award Grant Notice and Form of Performance Cash Award Agreement for the 2009 Equity Incentive Plan, as amended.
|
10.6
|
|
Lease, between Medical Technologies Systems, Inc. and Gateway Business Centre, Ltd., dated March 31, 2004.
|
10.7
|
|
First Lease Amendment, between Medical Technology Systems, Inc. and Gateway Business Centre, Ltd., dated July 26, 2004.
|
10.8
|
|
Lease, between MTS Medication Technologies, Ltd. and SAL Pension Fund, Ltd., dated June 9, 2011.
|
31.1
|
|
Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.
|
31.2
|
|
Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.
|
32.1
|
|
Certifications required by Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended, and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350).
|
101.INS(7)
|
|
XBRL Instance Document.
|
101.SCH(7)
|
|
XBRL Taxonomy Extension Schema Document.
|
101.CAL (7)
|
|
XBRL Taxonomy Extension Calculation Linkbase Document.
|
101.DEF(7)
|
|
XBRL Taxonomy Extension Definition Linkbase Document.
|
101.LAB(7)
|
|
XBRL Taxonomy Extension Label Linkbase Document.
|
101.PRE(7)
|
|
XBRL Taxonomy Extension Presentation Linkbase Document.
|
|
|
|
|
|
(1)
|
Previously filed as Exhibit 2.1 to the Registrant's Current Report on Form 8-K (File No. 000-33043) filed with the Securities Exchange Commission on May 2, 2012, and incorporated herein by reference.
|
(2)
|
Previously filed as an exhibit to the Registrant’s Registration Statement on Form S-1 (File No. 333-57024), and amendments thereto, originally filed with the Securities and Exchange Commission on March 14, 2001, and incorporated herein by reference.
|
(3)
|
Previously filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q (File No. 000-33043) filed with the Securities and Exchange Commission on August 9, 2010, and incorporated herein by reference.
|
(4)
|
Previously filed as an exhibit to the Registrant’s Annual Report on Form 10-K (File No. 000-33043), and amendments thereto, originally filed with the Securities and Exchange Commission on March 28, 2003, and incorporated herein by reference.
|
(5)
|
Previously filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q (File No. 000-33043) filed with the Securities and Exchange Commission on August 9, 2007, and incorporated herein by reference.
|
(6)
|
Previously filed as an exhibit to the Registrant’s Current Report on Form 8-K (File No. 000-33043) filed with the Securities and Exchange Commission on February 14, 2003, and incorporated herein by reference.
|
(7)
|
Pursuant to applicable securities laws and regulations, we are deemed to have complied with the reporting obligation relating to the submission of interactive data files in such exhibits and are not subject to liability under any anti-fraud provisions of the federal securities laws as long as we have made a good faith attempt to comply with the submission requirements and promptly amend the interactive data files after becoming aware that the interactive data files fails to comply with the submission requirements. Users of this data are advised that, pursuant to Rule 406T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act, are deemed not filed for purposes of section 18 of the Exchange Act and otherwise are not subject to liability under these sections.
|
|
OMNICELL, INC.
|
|
|
|
|
Date: August 9, 2012
|
|
|
/s/ ROBIN G. SEIM
|
|
Robin G. Seim
|
|
Duly Authorized Officer, Chief Financial Officer and Vice President Finance, Administration and Manufacturing
|
Exhibit
No.
|
|
Exhibit Title
|
2.1(1)
|
|
Agreement and Plan of Merger, dated as of April 26, 2012, by and among Omnicell, Inc., Mercury Acquisition Corp, MedPak Holdings, Inc. and Excellere Capital Management, LLC.
|
3.1(2)
|
|
Amended and Restated Certificate of Incorporation of Omnicell, Inc.
|
3.2(3)
|
|
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Omnicell, Inc.
|
3.3(4)
|
|
Certificate of Designation of Series A Junior Participating Preferred Stock.
|
3.4(5)
|
|
Bylaws of Omnicell, Inc., as amended.
|
4.1(2)
|
|
Form of Common Stock Certificate.
|
4.2
|
|
Reference is made to Exhibits 3.1, 3.2, 3.3 and 3.4.
|
4.3(6)
|
|
Rights Agreement, dated February 6, 2003, between Omnicell, Inc. and EquiServe Trust Company, N.A.
|
10.1*
|
|
Omnicell, Inc. Amended and Restated Severance Benefit Plan.
|
10.2*
|
|
Offer Letter, dated May 24, 2012, between Omnicell, Inc. and William Shields.
|
10.3*
|
|
Change of Control Agreement, dated May 23, 2012, between Omnicell, Inc. and William Shields and Addendum thereto dated June 24, 2012.
|
10.4*
|
|
Form of Restricted Stock Unit Award Agreement for the 2009 Equity Incentive Plan, as amended.
|
10.5*
|
|
Form of Performance Cash Award Grant Notice and Form of Performance Cash Award Agreement for the 2009 Equity Incentive Plan, as amended.
|
10.6
|
|
Lease, between Medical Technologies Systems, Inc. and Gateway Business Centre, Ltd., dated March 31, 2004.
|
10.7
|
|
First Lease Amendment, between Medical Technology Systems, Inc. and Gateway Business Centre, Ltd., dated July 26, 2004.
|
10.8
|
|
Lease, between MTS Medication Technologies, Ltd. and SAL Pension Fund, Ltd., dated June 9, 2011.
|
31.1
|
|
Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.
|
31.2
|
|
Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.
|
32.1
|
|
Certifications required by Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended, and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350).
|
101.INS(7)
|
|
XBRL Instance Document.
|
101.SCH(7)
|
|
XBRL Taxonomy Extension Schema Document.
|
101.CAL (7)
|
|
XBRL Taxonomy Extension Calculation Linkbase Document.
|
101.DEF(7)
|
|
XBRL Taxonomy Extension Definition Linkbase Document.
|
101.LAB(7)
|
|
XBRL Taxonomy Extension Label Linkbase Document.
|
101.PRE(7)
|
|
XBRL Taxonomy Extension Presentation Linkbase Document.
|
|
|
|
|
|
(1)
|
Previously filed as Exhibit 2.1 to the Registrant's Current Report on Form 8-K (File No. 000-33043) filed with the Securities Exchange Commission on May 2, 2012, and incorporated herein by reference.
|
(2)
|
Previously filed as an exhibit to the Registrant’s Registration Statement on Form S-1 (File No. 333-57024), and amendments thereto, originally filed with the Securities and Exchange Commission on March 14, 2001, and incorporated herein by reference.
|
(3)
|
Previously filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q (File No. 000-33043) filed with the Securities and Exchange Commission on August 9, 2010, and incorporated herein by reference.
|
(4)
|
Previously filed as an exhibit to the Registrant’s Annual Report on Form 10-K (File No. 000-33043), and amendments thereto, originally filed with the Securities and Exchange Commission on March 28, 2003, and incorporated herein by
|
(5)
|
Previously filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q (File No. 000-33043) filed with the Securities and Exchange Commission on August 9, 2007, and incorporated herein by reference.
|
(6)
|
Previously filed as an exhibit to the Registrant’s Current Report on Form 8-K (File No. 000-33043) filed with the Securities and Exchange Commission on February 14, 2003, and incorporated herein by reference.
|
(7)
|
Pursuant to applicable securities laws and regulations, we are deemed to have complied with the reporting obligation relating to the submission of interactive data files in such exhibits and are not subject to liability under any anti-fraud provisions of the federal securities laws as long as we have made a good faith attempt to comply with the submission requirements and promptly amend the interactive data files after becoming aware that the interactive data files fails to comply with the submission requirements. Users of this data are advised that, pursuant to Rule 406T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act, are deemed not filed for purposes of section 18 of the Exchange Act and otherwise are not subject to liability under these sections.
|
|
OMNICELL, INC.
|
||
|
|
||
|
|
||
|
By:
|
|
|
|
|
|
|
|
Title:
|
|
|
|
|
|
|
|
EMPLOYEE
|
||
|
|
||
|
|
||
|
Name:
|
|
|
|
|
||
|
Date:
|
|
|
|
|
|
|
|
EMPLOYEE
|
||
|
|
||
|
|
||
|
Name:
|
|
|
|
|
||
|
Date:
|
|
|
|
|
|
|
|
|
|
|
|
EMPLOYEE
|
||
|
|
||
|
|
||
|
Name:
|
|
|
|
|
||
|
Date:
|
|
|
|
|
|
|
|
Appendix A Adopted: June 20, 2009
|
||
|
|
||
|
OMNICELL, INC.
|
||
|
|
||
|
|
||
|
By:
|
|
|
|
|
||
|
Title:
|
|
|
|
|
|
|
Years of Service
|
|
Months of Base Salary
|
1
|
|
1 month
|
2
|
|
2 months
|
3
|
|
3 months
|
For each 5 Years of Service
|
|
1 extra month
|
|
Appendix B Adopted: June 20, 2009
|
||
|
|
||
|
OMNICELL, INC.
|
||
|
|
||
|
|
||
|
By:
|
|
|
|
|
||
|
Title:
|
|
|
|
|
|
|
Years of Service
|
|
Months of Base Salary
|
Not relevant
|
|
4 months
|
For each 5 Years of Service
|
|
1 extra month
|
|
Appendix B Adopted: June 20, 2009
|
||
|
|
||
|
OMNICELL, INC.
|
||
|
|
||
|
|
||
|
By:
|
|
|
|
|
||
|
Title:
|
|
|
|
|
|
|
Years of Service
|
|
Months of Base Salary
|
Not relevant
|
|
6 months
|
For each 5 Years of Service
|
|
2 extra months
|
|
Appendix B Adopted: June 20, 2009
|
||
|
|
||
|
OMNICELL, INC.
|
||
|
|
||
|
|
||
|
By:
|
|
|
|
|
||
|
Title:
|
|
|
|
|
|
|
Years of Service
|
|
Months of Base Salary
|
Not relevant
|
|
12 months
|
For each 5 Years of Service
|
|
2 extra months
|
|
Appendix B Adopted: June 20, 2009
|
||
|
|
||
|
OMNICELL, INC.
|
||
|
|
||
|
|
||
|
By:
|
|
|
|
|
||
|
Title:
|
|
|
|
|
|
|
1.
|
A lump sum amount equal to your annual base salary, in addition to any Unpaid Bonus Payment and any Unpaid Current Period Bonus Payment (each as defined in the MTS Employment Agreement), all subject to payroll withholding and deduction, and payable on the sixtieth (60
th
) day following the date of employment termination;
|
2.
|
For up to twelve (12) months beginning on the termination date (the “
COBRA Premiums Period
”), the Company will pay an amount toward your COBRA premiums, equivalent to the Company’s share of the health care coverage premiums paid by the Company on your behalf while you were a participant in the group health insurance coverage in effect as of the termination date (the “
COBRA Premiums Amount
”), provided you timely elect continued coverage under COBRA. You will remain responsible for an amount equal to your share of health care coverage premiums, and the COBRA administrative fee. If Omnicell determines, in its sole discretion, that it cannot pay the COBRA Premiums Amount without a substantial risk of violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company instead shall pay to you, on the first day of each month, a cash payment equal to the applicable COBRA Premiums Amount for that month, subject to applicable tax withholdings (such amount, the “
Special Cash Payment
”), during the COBRA Premiums Period. You may, but are not obligated to, use such Special Cash Payment toward the cost of COBRA premiums. If, during the COBRA Premiums Period, you become covered by group health insurance coverage through another employer or otherwise you cease to be eligible for COBRA, you must immediately notify Omnicell in writing of such event.
|
/s/ Randall A. Lipps
|
|
6/22/2012
|
|
By: Randall A. Lipps
|
Date
|
/s/ William Shields
|
|
6/24/2012
|
|
William Shields
|
Date
|
GESDMS/6583294.3
|
1
.
|
|
GESDMS/6583294.3
|
2
.
|
|
GESDMS/6583294.3
|
3
.
|
|
GESDMS/6583294.3
|
4
.
|
|
GESDMS/6583294.3
|
5
.
|
|
GESDMS/6583294.3
|
6
.
|
|
GESDMS/6583294.3
|
7
.
|
|
GESDMS/6583294.3
|
8
.
|
|
GESDMS/6583294.3
|
9
.
|
|
GESDMS/6583294.3
|
10
.
|
|
GESDMS/6583294.3
|
11
.
|
|
ATTACHMENTS
:
|
Performance Cash Award Agreement and 2009 Equity Incentive Plan
|
|
[Address]
|
Date: August 9, 2012
|
|
|
/s/ Randall A. Lipps
|
|
Randall A. Lipps
|
|
President and Chief Executive Officer
|
Date: August 9, 2012
|
|
|
/s/ Robin G. Seim
|
|
Robin G. Seim
|
|
Chief Financial Officer and Vice President Finance, Administration and Manufacturing
|
/s/ Randall A. Lipps
|
|
/s/ Robin G. Seim
|
Randall A. Lipps
|
|
Robin G. Seim
|
President and Chief Executive Officer
|
|
Chief Financial Officer and Vice President Finance,
Administration and Manufacturing
|